NasdaqGS:JAZZPharmaceuticals
Jazz’s 2025 Net Loss and 2026 Outlook Might Change The Case For Investing In JAZZ
In February 2026, Jazz Pharmaceuticals reported fourth-quarter 2025 results showing revenue rising to US$1.20 billion and net income of US$203.45 million, while full-year revenue increased to US$4.27 billion but swung to a net loss of US$356.15 million.
The company also issued 2026 revenue guidance of US$4.25 billion to US$4.50 billion, offering investors a tighter view of expected top-line performance despite the prior-year loss.
We’ll now examine how the full-year net loss alongside the...